By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Push Accelerates for Artificial Pancreas for Type 1 Diabetes
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Push Accelerates for Artificial Pancreas for Type 1 Diabetes
BusinessMedical Innovations

Push Accelerates for Artificial Pancreas for Type 1 Diabetes

PatrickDriscoll
PatrickDriscoll
Share
2 Min Read
SHARE

By recently releasing guidelines for premarket approval and investigation device exemption of “artificial pancreas” devices, the FDA set the stage for approval of these systems in the management of type 1 diabetes. 

By recently releasing guidelines for premarket approval and investigation device exemption of “artificial pancreas” devices, the FDA set the stage for approval of these systems in the management of type 1 diabetes. 

The term “artificial pancreas” derives from the potential ability of devices to artificially replace the functions of healthy pancreases in regulating blood glucose, a function that has been lost in type 1 diabetics.  The components of artificial pancreases are principally an insulin pump, a continuous blood glucose monitor and the necessary algorithm or controls to enable feedback from the glucose monitor to regulate insulin infusion rates.  Insulin pumps have been on the market for a number of years and sales of approved versions of continuous blood glucose monitors have begun to escalate.  Systems combining both pumps and monitors are also on the market but currently not in what is known as “closed loop” systems in which glucose levels are regulated by varying insulin infusion rates directly, without patient intervention.  Given the variables impacting blood glucose levels and the potential for inadequately regulated insulin infusion to result in dangerous hypoglycemia, the technology of safely closing the loop of glucose/insulin regulation has been a challenge, at least in terms of meeting FDA approval.

A number of companies are active in the development of closed loop, “artificial pancreas” systems including J&J/Animas Systems, DexCom, Medtronic and others. 

More Read

New Test Predicts Which Cancers will Spread
Cost of Injection Jumps from $15 to $1,500
PepsiCo Tries Medical Tourism
How Synoptic Reporting Supports Patient Outcomes Analysis
Obama’s Precision Healthcare Initiative Ushers in a New Age of Medical Marketing

Products, technologies and companies in the field of diabetes are the subject of the MedMarket Diligence report $D510.

     

TAGGED:artificial pancreasdiabeteshealthcare businessmedical innovations
Share This Article
Facebook Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

Medical InnovationsTechnology

Top 5 Reasons For Blockchain Implementation In Healthcare In 2019

January 28, 2019

Explaining Our Debt Problem

September 8, 2011
WIIFM political talk
BusinessHospital AdministrationSocial Media

Hillary Clinton’s Classic Mistake: A Marketing Lesson for Doctors and Hospitals

February 16, 2016
corporate wellness programs
BusinessPolicy & LawPublic HealthWellness

Wellbeing Starts in the C-Suite

March 17, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?